Greenwich LifeSciences (NASDAQ:GLSI) Cut to “Sell” at Wall Street Zen

Greenwich LifeSciences (NASDAQ:GLSI) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research note on Friday, May 15th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Greenwich LifeSciences has a consensus rating of “Hold” and an average price target of $47.50.

Greenwich LifeSciences Trading Down 6.0%

Shares of GLSI opened at $22.25 on Friday. Greenwich LifeSciences has a 12-month low of $7.78 and a 12-month high of $34.10. The firm has a 50-day moving average price of $24.91 and a 200 day moving average price of $22.38. The firm has a market capitalization of $326.63 million, a P/E ratio of -14.17 and a beta of 1.40.

Greenwich LifeSciences (NASDAQ:GLSI) last announced its earnings results on Monday, June 1st. The company reported ($0.58) earnings per share for the quarter. Equities research analysts predict that Greenwich LifeSciences will post -1.35 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of America Corp DE boosted its stake in shares of Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after purchasing an additional 1,322 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Greenwich LifeSciences by 109.6% in the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock valued at $165,000 after purchasing an additional 4,102 shares during the period. Rhumbline Advisers boosted its stake in shares of Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after purchasing an additional 3,168 shares during the period. Jane Street Group LLC purchased a new position in shares of Greenwich LifeSciences in the fourth quarter valued at approximately $203,000. Finally, Barclays PLC boosted its stake in shares of Greenwich LifeSciences by 11.8% in the fourth quarter. Barclays PLC now owns 9,744 shares of the company’s stock valued at $205,000 after purchasing an additional 1,030 shares during the period. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.